Article info
PDFLetter
Risk of multiple sclerosis during tumour necrosis factor inhibitor treatment for arthritis: a population-based study from DANBIO and the Danish Multiple Sclerosis Registry
- Correspondence to Lene Dreyer, Department of Rheumatology, Entrance 5, 3rd floor, Copenhagen University Hospital Herlev and Gentofte, Kildegårdsvej 28, 2900-Hellerup, Denmark; lene.dreyer{at}dadlnet.dk
Citation
Risk of multiple sclerosis during tumour necrosis factor inhibitor treatment for arthritis: a population-based study from DANBIO and the Danish Multiple Sclerosis Registry
Publication history
- Received August 28, 2015
- Revised November 18, 2015
- Accepted November 24, 2015
- First published December 23, 2015.
Online issue publication
October 31, 2019
Article Versions
- Previous version (13 April 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/